OPKO Health Issues Additional $125M Of Senior Secured Notes To KKR's HealthCare Royalty For Non-Dilutive Funding
The newly issued notes are secured by OPKO’s royalty interests arising under its mazdutide license agreement with Eli Lilly and Company and mature in 2044, consistent with the maturity of OPKO’s existing HCRx notes
OPKO borrowed $125 million from an investment company by promising to share future money it makes from a medicine deal with Eli Lilly. This helps OPKO get cash without selling more company ownership, but means sharing those earnings later.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.